SCHEMBL12980452

SCHEMBL12980452

Cc1c(C(=O)Nc2ccc(-c3nc4ccccc4s3)c(O)c2)cccc1[N+](=O)[O-]

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.65
▸ RXFP1 Q9HBX9 5/20 0.65
▸ TP53 P04637 4/20 0.63
▸ SMN1; SMN2 Q16637 2/20 0.63
▸ BLM P54132 2/20 0.63
▸ LMNA P02545 2/20 0.61
▸ POLB P06746 4/20 0.57
▸ MEN1 O00255 5/20 0.55
▸ KMT2A Q03164 5/20 0.55
▸ RAB9A P51151 4/20 0.55
▸ NPC1 O15118 3/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ PSMD14 O00487 1/20 0.55
▸ CTDSP1 Q9GZU7 1/20 0.55
▸ ALDH1A1 P00352 1/20 0.52
▸ EGFR P00533 1/20 0.51
▸ INSR P06213 1/20 0.51
▸ IGF1R P08069 1/20 0.51
▸ PDGFRB P09619 1/20 0.51
▸ SRC P12931 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12980417 0.87 MAPT (0.73) MAPTRXFP1TP53SMN1; SMN2BLM
SCHEMBL16602336 0.86 MAPT (0.74) MAPTRXFP1TP53SMN1; SMN2BLM
SCHEMBL12963171 0.83 MAPT (0.82) MAPTRXFP1TP53SMN1; SMN2BLM
SCHEMBL12980388 0.82 MAPT (0.65) MAPTRXFP1TP53SMN1; SMN2BLM
SCHEMBL12981167 0.81 MAPT (0.65) MAPTRXFP1TP53SMN1; SMN2BLM
SCHEMBL4920918 0.81 RAB9A (0.80) MAPTTP53SMN1; SMN2BLMLMNA
SCHEMBL12963180 0.79 MAPT (0.80) MAPTRXFP1TP53SMN1; SMN2BLM
SCHEMBL12963451 0.77 RAB9A (0.69) MAPTRXFP1TP53SMN1; SMN2BLM
SCHEMBL24711803 0.77 EGFR (0.64) MAPTRXFP1TP53SMN1; SMN2BLM
SCHEMBL12963182 0.77 MAPT (0.83) MAPTRXFP1TP53SMN1; SMN2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150150852-A1 TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS SIGA TECHNOLOGIES, INC. (US) 2015-06-04 — — US disclosed
US-8993604-B2 Treatment and prevention of dengue virus infections SIGA TECHNOLOGIES, INC. (US) 2015-03-31 — — US disclosed
US-20120258079-A1 Treatment and Prevention of Dengue Virus Infections SIGA TECHNOLOGIES, INC. 2012-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150150852-A1 TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS HAVCR2, TTPA, CHIA MAPT 118/4885RXFP1 4348/4885TP53 2739/4885
US-20120258079-A1 Treatment and Prevention of Dengue Virus Infections HAVCR2, TTPA, CHIA MAPT 118/4885RXFP1 4348/4885TP53 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback